Avadel Pharmaceuticals (NASDAQ: AVDL) is one of 496 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Avadel Pharmaceuticals to similar businesses based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, valuation and dividends.

Earnings & Valuation

This table compares Avadel Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Avadel Pharmaceuticals $172.74 million $68.27 million 24.19
Avadel Pharmaceuticals Competitors $2.01 billion $135.76 million -3.49

Avadel Pharmaceuticals’ peers have higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Avadel Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avadel Pharmaceuticals 0 0 3 0 3.00
Avadel Pharmaceuticals Competitors 3071 9317 22336 660 2.58

Avadel Pharmaceuticals currently has a consensus price target of $22.67, indicating a potential upside of 202.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.40%. Given Avadel Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Avadel Pharmaceuticals is more favorable than its peers.

Risk & Volatility

Avadel Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals’ peers have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.


This table compares Avadel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avadel Pharmaceuticals 18.96% -13.95% -4.22%
Avadel Pharmaceuticals Competitors -2,976.15% -160.93% -30.80%

Insider and Institutional Ownership

69.6% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.3% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Avadel Pharmaceuticals beats its peers on 9 of the 13 factors compared.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.